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Nienhuis3,5, Bouke P.C. Hazenberg4,5 
1Medical Imaging Center, Department of Nuclear Medicine and Molecular Imaging, 
3Department of Internal Medicine, 4Department of Rheumatology & Clinical Immunology, 
5Amyloidosis Center of Expertise, University of Groningen, University Medical Center 
Groningen, The Netherlands, 2TechMed Centre, Department of Biomedical Photonic 
Imaging, University of Twente, Enschede, The Netherlands.
Cardiac amyloidosis (CA) or amyloid cardiomyopathy (ACM), resulting from extracellular 
deposition of amyloid fibrils, is an underestimated cause of heart failure and cardiac 
arrhythmias [1,2].  Amyloid cardiomyopathy is a restrictive form of cardiomyopathy (CM) 
characterized by diastolic dysfunction and should be suspected in any patient presenting 
with heart failure with preserved ejection fraction (HFpEF). The two main types of cardiac 
amyloidosis are AL-type, derived from misfolded immunoglobulin light chains, and ATTR-
type, derived from misfolded transthyretin (TTR) protein.
AL amyloidosis currently is the most common type of clinically significant cardiac 
amyloidosis, accounting for ~80% of all cases, invariably associated with an underlying clonal 
plasma cell dyscrasia and almost exclusively seen in individuals older than 40 years [3] 
Cardiac involvement is frequent (70%) in AL amyloidosis. It is usually associated with 
involvement of other organs and is rarely (<5%) limited as isolated cardiac amyloidosis. In 
early stages, ACM in AL amyloidosis is characterized by the presence of HFpEF. However, 
systolic dysfunction commonly follows in the course of the disease. [4].
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ATTR amyloidosis is increasingly recognized as a cardiomyopathy in elderly people, 
especially in men [5]. Amyloid in these cases has been derived from non-mutated, so-called 
wild-type TTR. ATTR amyloidosis can also sometimes be found as hereditary disease, caused 
by a mutation in the TTR gene, often with a clinical picture dominated by polyneuropathy. 
However, cardiomyopathy is usually part of the clinical picture, sometimes at presentation, 
but frequently it evolves in the course of the disease.
Accurate and early diagnosis of heart failure as a result of CA has major implications 
on prognosis and treatment. Selective treatment is delayed in a substantial proportion of the 
affected individuals because of an often late recognition, thereby negatively affecting the 
quality of life as well as the survival of these individuals. Therefore, there is a definite clinical 
need for early and secure diagnosis of cardiac amyloidosis as well as for reliable typing of 
cardiac amyloid as AL or ATTR type. Molecular imaging with PET and SPECT nowadays plays a 
critical role in the diagnosis, identification and distinction between ATTR and AL type CA. 
Several SPECT and PET tracers are available for diagnosing CA [6]. Selective tracers with the 
potential of discriminating ATTR from AL type CA with confidence, are the most important 
ones. 
Thioflavin-like agents (Pittsburgh Compound-B, florbetapir and florbetapen) bind 
directly to repetitive motifs on the exterior surface of the fibrils. Aprotinin has been used in 
the past to detect CA [7, 8] and it may also bind to repetitive motifs and/or electrostatically 
[9]. The accuracy of 99mTc-aprotinin scintigraphy has been reported previously for systemic 
amyloidosis, but not specifically for cardiac AL amyloidosis. A potential concern of the bovine 
lung tissue origin of aprotinin is the possible transfer of Bovine Spongiform Encephalopathy 
(BSE). The manufacturing process, however, contains a number of inactivation/removal 
steps to reduce the possibility of BSE in the order of 18 log 10, thereby leading to the 
conclusion that aprotinin is BSE safe [10].
The current study of Awaya and colleagues in this issue, evaluated the performance 
of 99mTc-aprotinin scintigraphy for diagnosing AL CA in a pilot study consisting of 10 patients 
suspected of suffering from amyloidosis [11]. Cardiac amyloidosis was histologically 
confirmed by endomyocardial biopsy in 5 of 10 patients. 99mTc-aprotinin (planar images) was 
positive in 4 out of 5 patients who had amyloid deposits in endomyocardial biopsy. On the 
other hand, all 5 patients without amyloid deposits were negative in planar image. 99mTc-
aprotinin SPECT/CT imaging was positive in all 5 patients who had amyloid deposits, but also 
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showed subtle myocardial tracer uptake in 3 out of 5 patients (false positive) in whom an 
endomyocardial biopsy did not show amyloid. It was concluded that 99mTc-aprotinin 
scintigraphy including SPECT/CT may be valuable for the noninvasive diagnosis of AL cardiac 
amyloidosis. However, before this application can be implemented as a reliable non-invasive 
technique within the general work-up of patients with the suspicion of AL amyloidosis, 
further research is required in a substantial number of patients with cardiac amyloidosis and 
controls, especially aiming to reduce false-positive findings on SPECT/CT.  Quantification of 
the heart-to-background ratio may be beneficial in this respect, by setting an upper 
reference limit to reduce false positive findings [8]
Although this pilot study consisted of a small, heterogeneous patient cohort, 
including treatment-naïve as well as pre-treated patients, it underlines the clinical value of 
applying new more specific imaging tracers in cardiac imaging, but the false positive findings 
with SPECT/CT should be kept in mind. 
Selective radiopharmaceuticals are the benzothiazoles 11C–Pittsburgh compound-B (11C-PiB) 
and 18F–florbetaben, while 18F–florbetapir is a stilbene derivative with a very similar 
structure. A systematic review of the application of PET imaging with 11C-PiB, 18F-florbetapir 
and 18F-florbetaben in 6 studies (n=98 subjects) demonstrated a sensitivity of 92% and a 
specificity of 83% for the detection of AL and ATTR CA [12]. 
11C-PiB is however only available in centers with an on-site cyclotron. Further it is 
reported that 11C-PIB and the 18F-labeled thioflavin-like agents detect deposition of several 
types of amyloid (AL-kappa, AL-lambda, and TTR origin) in the heart, representing a less 
specific detection of amyloid [13,14]. 
Compared with control samples, mean 18F-florbetapir-specific uptake is significantly 
higher in the amyloid samples, and higher in AL CA compared with the ATTR CA samples [14]
99mTc-aprotinin scintigraphy was directly compared with 11C-PiB in AL CA, and 99mTc-
aprotinin scintigraphy appears to offer a sensitive, specific diagnostic modality for patients 
with amyloidosis [15]. More specific targeted imaging may also result in more personalized 
therapy. However, this was based on small patient numbers and there is a need for studies 
comparing the different tracers mentioned above in substantial numbers of patients with 
well-defined types of cardiac amyloidosis and in well-defined cardiomyopathy controls who 
present themselves in a similar way.
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It has been shown that chemotherapy including high-dose melphalan followed by 
peripheral blood stem cell transplantation can be effective if the load of AL amyloidosis has 
not progressed too far and cardiac involvement is subtle [16]. However, usually cardiac 
disease is detected too late and the risks are too high in these patients with AL CA to benefit 
from intensive chemotherapy. There is little time for patients with symptomatic cardiac AL 
amyloidosis to respond to treatment and therefore the prognosis of symptomatic cardiac AL 
amyloidosis is still grim, stressing the importance of early detection. Monitoring the load of 
cardiac amyloid will be a useful tool in patients receiving treatment. Manwani et al. 
evaluated cardiac uptake with 18F-florbetapir PET in patients with systemic AL amyloidosis 
and cardiac involvement before and after treatment, as well as its serial utility in monitoring 
in 15 patients [17]. 
In summary, the role of molecular imaging in CA is significant in, (1) differentiating between 
AL and ATTR CA, (2) defining the extent of systemic amyloid manifestations, and (3) as a 
potential biomarker for treatment monitoring. Biphophonate scintigraphy is a strong tool for 
detecting ATTR CA, and will be negative in AL CA. At the other side the 18F-labeled thioflavin-
like agents are favorable in AL CA detection. Smart application or combination of these 
tracers is needed to optimally differentiate ATTR from AL CA.  For diagnostic considerations, 
specific target imaging will play a role in the future. Several aspects have to be elucidated 
yet, but if aprotinin and other selective radiopharmaceuticals finally will break through as 
diagnostic and potential therapeutic possibilities in amyloidosis, molecular imaging might 
become an excellent tool to guide the clinician in diagnosing and treating the patient with 
cardiac amyloidosis. To overcome the spatial limitations of SPECT and to improve the 
accuracy of the imaging technique, radiolabeled-aprotinin with a PET isotope should be 
considered in future studies.
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